Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifevantage (LFVN) Net Income towards Common Stockholders (2016 - 2025)

Lifevantage's Net Income towards Common Stockholders history spans 16 years, with the latest figure at $273000.0 for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 89.46% year-over-year to $273000.0; the TTM value through Dec 2025 reached $7.8 million, up 7.54%, while the annual FY2025 figure was $9.8 million, 233.84% up from the prior year.
  • Net Income towards Common Stockholders reached $273000.0 in Q4 2025 per LFVN's latest filing, down from $2.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $4.9 million in Q2 2021 to a low of -$1.5 million in Q2 2022.
  • Average Net Income towards Common Stockholders over 5 years is $1.4 million, with a median of $1.5 million recorded in 2024.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 1439.24% in 2022, then surged 494.66% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $79000.0 in 2021, then crashed by 1439.24% to -$1.1 million in 2022, then soared by 38.0% to -$656000.0 in 2023, then soared by 494.66% to $2.6 million in 2024, then crashed by 89.46% to $273000.0 in 2025.
  • Per Business Quant, the three most recent readings for LFVN's Net Income towards Common Stockholders are $273000.0 (Q4 2025), $2.1 million (Q3 2025), and $2.0 million (Q2 2025).